Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – What’s Next?

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) shares gapped down before the market opened on Thursday . The stock had previously closed at $9.40, but opened at $8.83. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.20, with a volume of 497 shares.

Analysts Set New Price Targets

A number of research firms have recently commented on SGIOY. The Goldman Sachs Group raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 15th. Jefferies Financial Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 14th. Two investment analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Trading Down 2.1%

The company has a market capitalization of $15.57 billion, a P/E ratio of 9.15, a P/E/G ratio of 3.37 and a beta of 0.08. The company has a 50-day simple moving average of $9.07 and a 200 day simple moving average of $9.47. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.00 and a current ratio of 1.14.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last announced its quarterly earnings data on Monday, August 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.18. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.13%. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $970.69 million. Sell-side analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 earnings per share for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, the company has built its business around drug discovery and has a particular focus on infectious diseases, including antiviral and antibacterial treatments.

Shionogi’s products include Xofluza (baloxavir marboxil), an oral treatment for influenza, and Fetcroja (cefiderocol), an antibiotic used for certain difficult-to-treat bacterial infections.